Comparison of B-type natriuretic peptide assays for identifying heart failure in stable elderly patients with a clinical diagnosis of chronic obstructive pulmonary disease

European Journal of Heart Failure

Volumn 9, Issue 6-7, 2007, Pages 651-659

  Rutten, Frans H ^a   Cramer, Maarten Jan M ^a   Zuithoff, Nicolaas P A ^a   Lammers, Jan Willem J ^a   Verweij, Wim ^b   Grobbee, Diederick E ^a   Hoes, Arno W ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Department of Cardiology ^*  (Netherlands)

Author keywords

B type natriuretic peptides; Chronic obstructive pulmonary disease; Diagnosis; Heart failure

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; GENERAL PRACTITIONER; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION;

AGED; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; IMMUNOASSAY; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REFERENCE VALUES;

EID: 34248188260     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2007.01.010     Document Type: Article

References (40)

1. Remes J., Miettinen H., Reunanen A., and Pyörälä K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 12 (1991) 315-321
2. Cowie M.R., Struthers A.D., Wood D.A., et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 350 (1997) 1349-1353
3. Landray M.J., Lehman R., and Arnold I. Measuring brain natriuretic peptide in suspected left ventricular systolic dysfunction in general practice: cross-sectional study. BMJ 320 (2000) 985-986
4. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347 (2002) 161-167
5. McCullough P.A., Hollander J.E., Nowak R.M., et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med 10 (2003) 198-204
6. Rutten F.H., Moons K.G.M., Cramer M.J.M., et al. Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: a cross-sectional diagnostic study. BMJ 331 (2005) 1379
7. Lainchbury J.G., Campbell E., Frampton C.M., Yandle T.G., Nicholls M.G., and Richards A.M. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 42 (2003) 728-735
8. Rodeheffer R.J. Measuring plasma B-type natriuretic peptide in heart failure: good to go in 2004?. J Am Coll Cardiol 44 (2004) 740-749
9. Hunt P.J., Yandle T.G., Nicholls M.G., Richards A.M., and Espiner E.A. The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochem Biophys Res Commun 214 (1995) 1175-1183
10. Apple F.S., Panteghini M., Ravkilde J., et al. Quality specifications for B-type natriuretic peptide assays. Clin Chem 51 (2005) 486-493
11. Roche Diagnostics GmbH. Elecsys NT-proBNP [Package Insert] (2002), Roche Diagnostics GmbH, Mannheim, Germany
12. van der Merwe D.E., Henley R., Lane G., et al. Effect of different sample types and stability after blood collection of N-terminal pro-B-type natriuretic peptide as measured with Roche Elecsys system. Clin Chem 50 (2004) 779-780
13. Rutten F.H., Cramer M.J., Grobbee D.E., et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 26 (2005) 1887-1894
14. Rose G.A., and Blackburn H. Cardiovascular survey methods (1982), World Health Organisation, Geneva
15. Schiller N.B., Shah P.M., Crawford M., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2 (1989) 358-367
16. Folland E.D., Parisi A.F., Moynihan P.F., Jones D.R., Feldman C.L., and Tow D.E. Assessment of left ventricular ejection fraction and volumes by real-time, two-dimensional echocardiography. A comparison of cineangiographic and radionuclide techniques. Circulation 60 (1979) 760-766
17. Quinones M.A., Waggoner A.D., Reduto L.A., et al. A new, simplified and accurate method for determining ejection fraction with two-dimensional echocardiography. Circulation 64 (1981) 744-753
18. Tsang T.S., Barnes M.E., Gersh B.J., Bailey K.R., and Seward J.B. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol 90 (2002) 1284-1289
19. Garcia M.J., Thomas J.D., and Klein A.L. New Doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol 32 (1998) 865-875
20. Schena M., Clini E., Errera D., and Quadri A. Echo-Doppler evaluation of left ventricular impairment in chronic cor pulmonale. Chest 109 (1996) 1446-1451
21. Bossuyt P.M., Reitsma J.B., Bruns D.E., et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem 49 (2003) 7-18
22. Swedberg K., Cleland J., Dargie H., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 1115-1140
23. Vasan R.S., Benjamin E.J., and Levy D. Congestive heart failure with normal left ventricular systolic function. Clinical approaches to the diagnosis and treatment of diastolic heart failure. Arch Intern Med 156 (1996) 146-157
24. Harrell F.E., Lee K.L., and Mark D.B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15 (1996) 361-387
25. Cowie M.R., Jourdain P., Maisel A., et al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J 24 (2003) 1710-1718
26. Bland J.M., and Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1 (1986) 307-310
27. Pauwels R.A., Buist A.S., Ma P., Jenkins C.R., and Hurd S.S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care 46 (2001) 798-825
28. Fabbri L.M., and Hurd S.S. Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update. Eur Respir J 22 (2003) 1-2
29. Nielsen L.S., Svanegaard J., Klitgaard A., and Egeblad H. N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. Eur J Heart Fail 6 (2004) 63-70
30. Januzzi J.L., van Kimmenade R., Lainchbury J., et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 27 (2006) 330-337
31. Vasan R.S., Benjamin E.J., Larson M.G., et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA 288 (2002) 1252-1259
32. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., Mahoney D.W., Bailey K.R., and Burnett Jr. J.C. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation 109 (2004) 3176-3181
33. Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., and Richards A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 (2000) 1126-1130
34. Lang C.C., Coutie W.J., Struthers A.D., Dhillon D.P., Winter J.H., and Lipworth B.J. Elevated levels of brain natriuretic peptide in acute hypoxaemic chronic obstructive pulmonary disease. Clin Sci (Lond) 83 (1992) 529-533
35. Troughton R.W., Prior D.L., Pereira J.J., et al. Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol 43 (2004) 416-422
36. Moons K.G., Biesheuvel C.J., and Grobbee D.E. Test research versus diagnostic research. Clin Chem 50 (2004) 473-476
37. Moons K.G., and Grobbee D.E. When should we remain blind and when should our eyes remain open in diagnostic studies?. J Clin Epidemiol 55 (2002) 633-636
38. Cowie M.R., Wood D.A., Coats A.J., et al. Incidence and aetiology of heart failure; a population-based study. Eur Heart J 20 (1999) 421-428
39. Damarla M., Celli B.R., Mullerova H.X., and Pinto-Plata V.M. Discrepancy in the use of confirmatory tests in patients hospitalized with the diagnosis of chronic obstructive pulmonary disease or congestive heart failure. Respir Care 51 (2006) 1120-1124
40. Quanjer P.H., Tammeling G.J., Cotes J.E., Pedersen O.F., Peslin R., and Yernault J.C. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 16 (1993) 5-40